Michael Mazowiecki, MD
Neurology · Greensburg, PANPI 1841304581
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $460,418 of the $535,508 with a category attached, or 86.0%. It is spread thinly across 28 manufacturers, the largest accounting for just 16.5%. Reporting peaked in 2022 at $111,193 and has fallen 59.1% since, to $45,516 in 2025. Among neurology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 923 payments — averaging $580.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$88K
- Biogen$78K
- EMD Serono, Inc.$70K
- Acorda Therapeutics, Inc$55K
- Biohaven Pharmaceuticals, Inc.$45K
- Biohaven Pharmaceutical Holding Company Ltd.$38K
- plus $161K from 22 others
What the payments were for
- Consulting fees$28,4465%
- Speaking & faculty fees$460,41886%
- Travel & lodging$17,8103%
- Food & beverage$28,6975%
- Education$1380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 219 | $88,415 |
| Biogen | 72 | $77,763 |
| EMD Serono, Inc. | 129 | $69,521 |
| Acorda Therapeutics, Inc | 58 | $55,190 |
| Biohaven Pharmaceuticals, Inc. | 45 | $44,713 |
| Biohaven Pharmaceutical Holding Company Ltd. | 39 | $38,481 |
| Genentech USA, Inc. | 44 | $38,404 |
| Sanofi | 54 | $38,168 |
| E.r. Squibb & Sons, L.L.C. | 45 | $37,505 |
| Pfizer | 32 | $14,945 |
| Lilly USA, LLC | 19 | $8,216 |
| Bristol Myers Squibb | 70 | $7,083 |
| Harmony Biosciences LLC | 14 | $5,787 |
| Johnson & Johnson | 15 | $5,309 |
| UCB, Inc. | 7 | $1,681 |
| TG Therapeutics, Inc. | 11 | $1,438 |
| AstraZeneca | 10 | $567 |
| Novartis | 11 | $531 |
| Neurocrine Biosciences, Inc. | 4 | $379 |
| Livanova USA, Inc. | 5 | $340 |
| Amgen | 4 | $260 |
| Mallinckrodt Hospital Products Inc. | 9 | $167 |
| Greenwich Biosciences, Inc. | 1 | $128 |
| Lundbeck LLC | 2 | $125 |
| Mallinckrodt Enterprises LLC | 1 | $122 |
| MDD US Operations, LLC | 1 | $122 |
| SK Life Science, Inc. | 1 | $120 |
| Bausch Health US, LLC | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$535,508 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WakixPitolisant Hcl | 29 | $416,431 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 26 | $279,730 |
| VumerityDiroximel Fumarate | 17 | $145,537 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $141,987 |
| ZeposiaOzanimod Hydrochloride | 11 | $99,590 |
| Emgality PenGalcanezumab-Gnlm | 134 | $99,458 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 12 | $97,600 |
| Nurtec OdtRimegepant Sulfate | 86 | $84,909 |
| Tetrabenazine | 13 | $76,023 |
| UbrelvyUbrogepant | 71 | $71,277 |
| Aimovig AutoinjectorErenumab-Aooe | 98 | $70,878 |
| Dalfampridine ErDalfampridine | 38 | $46,278 |
| QuliptaAtogepant | 29 | $30,097 |
| RytaryCarbidopa/Levodopa | 20 | $24,568 |
| VimpatLacosamide | 19 | $20,242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Harmony Biosciences LLCWakix | $5,787 | $416,43129 claims |
| PfizerOctagam, Nurtec Odt, Dilantin | $14,945 | $366,677127 claims |
| BiogenVumerity | $77,763 | $145,53717 claims |
| AbbVieUbrelvy, Qulipta | $88,415 | $101,374100 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $37,505 | $99,59011 claims |
| UCB, Inc.Vimpat, Neupro | $1,681 | $28,77530 claims |
| Neurocrine Biosciences, Inc.Ongentys | $379 | $15,15815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Greensburg
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Jill Giordano FarmerPhiladelphia$1.2M
- Ravi DukkipatiYork$936K
- Brad KleinAbington$927K
- Stephanie Nahas-GeigerPhiladelphia$786K
- John KhouryAbington$686K
- Amit Bar-OrPhiladelphia$596K
- Behrang SaminejadAllentown$594K
- Anoopum GuptaPittsburgh$592K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.